LGVN - Long-term Survival Data from Longeveron's ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association | Benzinga
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company's ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome (HLHS) has been accepted for presentation as a poster at the upcoming meeting of the American Heart Association (AHA).
The poster, titled Long-term Transplant-free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-based Therapy (Sunjay Kaushal, et al.), will be presented at the Scientific Sessions of the American Heart Association, to be held in Philadelphia, PA, November 11-13, 2023.
Longeveron previously announced long-term survival data from the ELPIS 1 trial, which showed children in the trial had 100% survival up to 5 years of age after receiving Lomecel-B™ compared to 20% mortality rate observed from historical control data. Lomecel-B™ has received Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation by the US Food and Drug Administration (FDA) for the HLHS indication.
About the Longeveron Rights Offering
As a reminder, there is an ongoing, effective rights offering on the registration statement previously filed with the Securities and Exchange Commission to conduct a tradable, subscription rights offering. The rights offering is being made through a distribution of five tradable subscription rights (to be listed on the NASDAQ Capital Market under the ticker symbol LGVNR) to purchase shares of Class A common stock for each share of common stock and warrant to purchase common stock owned on the record date, at a $3.00 subscription price per share.
The calendar for the rights offering is as follows:
Thursday, August 17 |
LGVNV Rights begin to trade. |
Friday, August 18 |